New imaging test for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new imaging agent called RYZ711 to help see prostate cancer more clearly on a PET/CT scan. It is for people with prostate cancer at different stages, and it might help doctors choose the best treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer (confirmed by biopsy).
- You are able to care for yourself (ECOG score 2 or less).
- You are already scheduled to have a PSMA PET/CT scan.
- You are in one of these groups: before surgery for intermediate- or high-risk cancer, have rising PSA after treatment, or have advanced prostate cancer that has spread and is still growing.
- Your kidneys, heart, and liver are working well enough (no severe problems).
- You do not have a rare type of prostate cancer (like neuroendocrine) or other cancers that have spread from somewhere else.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that targets a protein called PSMA found on prostate cancer cells. It uses a radioactive form of the treatment to try to kill cancer cells while limiting damage to healthy cells. This study is for men with advanced prostate cancer that has stopped responding to other treatments.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This study is testing whether a special scan (dosimetry) can help predict how well PSMA radioligand therapy works for men with advanced prostate cancer that has spread. The therapy uses a radioactive drug to target and kill cancer cells that have a protein called PSMA.
This study tests a new imaging agent (68Ga-NYM032) used with PET/CT scans to help doctors better detect prostate cancer before surgery. If you have biopsy-confirmed prostate cancer and are planning to have your prostate removed, this trial may help evaluate whether this new imaging method improves cancer detection.
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.